PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of retrovirBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleRetrovirologyJournal Front Page
 
Retrovirology. 2010; 7(Suppl 1): P173.
Published online 2010 May 11. doi:  10.1186/1742-4690-7-S1-P173
PMCID: PMC2890964

Auto-immune thrombocytopenia after Measles Mumps Rubella MMR vaccination: molecular mimicry of measles virus phosphoprotein with platelet gpIIb

Background

MMR vaccination is complicated by rare cases of auto-immune purpura or thrombocytopenia in a chronological delay of about 10-24 days, which corresponds to the rise of antibodies (Autret E, 1996; Vlacha V, 1996). We have demonstrated that in the cases of HIV-1, Parvovirus B19, Chikungunya virus, Leptospirosis, the culprit is an epitope localized on the platelet gpIIIaIIb, centred by a phenylalanine-proline (Tran MKG, ISHEID Toulon 2002); these auto-antibodies are very powerful and induce in mice a thrombocytopenia; allo-immunisation from mother to the newborn has the same epitope on gpIIIaIIb (Brouk H, 2009). We continue the same direction of research for MMR vaccine.

Methods

Comparison of amino acid sequences between gpIIIaIIb and viruses (measles, mumps and rubella).

Results

There is a molecular mimicry between gpIIb (P08514) and measles virus (strain MVi/Victoria.Aus/12.99) Phosphoprotein P (ABV24494) (Bankamp B, 2008), Table 1.

Discussion

The occurrence of thrombocytopenia 2 or 3 weeks after MMR vaccination is an auto-immune phenomenon, on a peculiar genetic background prone to make auto-antibodies against phenylalanine-proline containing epitopes. MMR vaccine must be avoided in these patients with idiopathic thrombocytopenia (Drachtman RA, 1994). The chronological argument is by itself convincing and confirmed here by the biological finding of the causal epitope on platelet. Thus we must be very cautious in presence of a MMR vaccine clinical auto-immune complication (such as autism) (Wakefield AJ) and not discard it as a simple coincidence, but rather try to elucidate its mechanism and genetics (HLA-DR4). The gpIIIaIIb epitope may serve as a chelating hapten for treatment.


Articles from Retrovirology are provided here courtesy of BioMed Central